OKYO Pharma (OKYO Pharma) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2023)

View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. OKYO Pharma's long-term debt to total assests ratio for the quarter that ended in Mar. 2023 was 0.00.

OKYO Pharma's long-term debt to total assets ratio stayed the same from Mar. 2022 (0.00) to Mar. 2023 (0.00).

OKYO Pharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for OKYO Pharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma LT-Debt-to-Total-Asset Chart

OKYO Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.01

OKYO Pharma Semi-Annual Data
	Sep13	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	-	-	-

OKYO Pharma LT-Debt-to-Total-Asset Calculation

OKYO Pharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	0	/	5.204
	=

OKYO Pharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (Q: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2023 )	/	Total Assets (Q: Mar. 2023 )
	=	0	/	5.204
	=

OKYO Pharma (NAS:OKYO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

OKYO Pharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

OKYO Pharma (OKYO Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

OK10:Germany

Address

14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ

Website

https://www.okyopharma.com

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Executives

John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: Chief Executive Officer
Gabriele M Cerrone	director, 10 percent owner, officer: Executive Chairman	265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer	director	C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon	director	PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah	officer: Chief Financial Officer	55 PARK LANE, LONDON X0 W1K 1NA